St. Jude Sees Multiple Growth Opportunities For Vascular Access Closure
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical is counting on increases in atrial fibrillation ablation, aneurysm repair and minimally invasive valve implants to expand the market for its femoral artery access closure devices
You may also be interested in...
FDA Approves J&J’s Navistar ThermoCool For Atrial Fibrillation Ablation
With PMA approval Feb. 6, Johnson & Johnson/Biosense Webster's NaviStar ThermoCool and EZ Steer ThermoCool Navigational became the first cardiac ablation catheters approved by FDA specifically for treatment of atrial fibrillation
Holiday Shopping: St. Jude Adds To A-Fib, Cardio Units With Two Acquisitions
St. Jude Medical acquired two privately-held firms just before the New Year for a total of $550 million, gaining tools for artery lesion assessment and precise interventional procedure navigation, among other technologies
St. Jude Daig Division Splits To Emphasize Vascular Closure, AF Devices
Newly appointed president of St. Jude Medical's cardiology division Paul Buckman will work to retain AngioSeal's number-one position in the U.S. vascular closure device market as newcomer Abbott Labs tries to gain ground